Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 10/20 | 0.68 |
| ▸ | KIT | P10721 | 10/20 | 0.66 |
| ▸ | BCR | P11274 | 4/20 | 0.66 |
| ▸ | DDR1 | Q08345 | 4/20 | 0.66 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.66 |
| ▸ | CSF1R | P07333 | 6/20 | 0.65 |
| ▸ | RET | P07949 | 1/20 | 0.65 |
| ▸ | ABL2 | P42684 | 2/20 | 0.62 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.62 |
| ▸ | EGFR | P00533 | 3/20 | 0.61 |
| ▸ | BRAF | P15056 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9610802 | 0.94 | ABL1 (0.70) | ABL1KITBCRDDR1DDR2 | |
| SCHEMBL9611028 | 0.92 | ABL1 (0.58) | ABL1KITBCRDDR1DDR2 | |
| SCHEMBL9611105 | 0.91 | ABL1 (0.69) | ABL1KITBCRCSF1RRET | |
| SCHEMBL15871941 | 0.89 | ABL1 (0.69) | ABL1KITBCRDDR1DDR2 | |
| SCHEMBL10265846 | 0.89 | ABL1 (0.68) | ABL1KITBCRDDR1DDR2 | |
| SCHEMBL9611036 | 0.87 | ABL1 (0.75) | ABL1KITBCRDDR1CSF1R | |
| SCHEMBL9610979 | 0.87 | ABL1 (0.69) | ABL1KITBCRDDR1DDR2 | |
| SCHEMBL9610728 | 0.86 | ABL1 (0.74) | ABL1KITBCRDDR1DDR2 | |
| SCHEMBL10207568 | 0.85 | ABL1 (0.79) | ABL1KITBCRDDR1DDR2 | |
| SCHEMBL9611109 | 0.84 | ABL1 (0.57) | ABL1KITBCRDDR1DDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9029533-B2 | Substituted acetylenic imidazo[1,2-A]pyridazines as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20140066434-A1 | Methods and Compositions for Treating Parkinson's Disease | ARIAD PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20130231337-A1 | Bicyclic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20120135986-A1 | Bicyclic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-8114874-B2 | Substituted acetylenic imidazo[1,2-B]pyridazine compounds as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20070191376-A1 | Bicyclic heteroaryl compounds | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066434-A1 | Methods and Compositions for Treating Parkinson's Disease | PARK7, SNCA, HTT | ABL1 2649/4885KIT 3528/4885BCR 4835/4885 |
| US-20070191376-A1 | Bicyclic heteroaryl compounds | CYP3A43, CYP11B2, CYP2F1 | ABL1 110/4885KIT 824/4885BCR 250/4885 |
| US-20130231337-A1 | Bicyclic Heteroaryl Compounds | CYP3A43, CYP11B2, CYP2F1 | ABL1 110/4885KIT 824/4885BCR 250/4885 |
| US-20120135986-A1 | Bicyclic Heteroaryl Compounds | CYP3A43, CYP11B2, CYP2F1 | ABL1 110/4885KIT 824/4885BCR 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.